This milestone marks a breakthrough after unsuccessful attempts to develop painkillers without the addictive potential of ...
The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller ...
Vertex Pharmaceuticals won FDA approval for its non-opioid painkiller Journavx. Vertex stock jumped in late trading.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...
FDA approves Journavx, a non-opioid medication for moderate to severe acute pain. Learn about its efficacy and side effects.
Vertex Pharmaceuticals (VRTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Terence ...
The US Food and Drug Administration (FDA) has approved Vertex Pharmaceuticals’ oral Journavx (suzetrigine) to treat adults ...
The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class ...
Vertex Pharmaceuticals Inc. (VRTX) has secured FDA approval for Suzetrigine, an oral, non-opioid, highly selective NaV1.8 pain signal ...
Vertex has gained the FDA's approval for its non-addictive pain med Journavx, which becomes the first significant innovation ...
U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated ...
The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...